Risdiplam

證據等級: L5

預測適應症: 1 個

RISDIPLAM: Evaluation Pending — Critical Data Gaps Prevent Full Assessment

One-Sentence Summary

Risdiplam (DrugBank ID: DB15305) is currently not marketed in Taiwan, and the TxGNN model returned no predicted indications in this Evidence Pack. Original indications, mechanism of action, and safety data are all absent, making it impossible to conduct a meaningful repurposing evaluation at this stage. This report documents the current state and specifies the data required to proceed.

Quick Overview

Item	Content
Original Indication	Not populated in this Evidence Pack
Predicted New Indication	No TxGNN predictions returned
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only (no actual studies linked)
Taiwan Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why No Prediction Is Available

The predicted_indications array in this Evidence Pack is empty. Without a TxGNN-predicted target indication, the standard repurposing pipeline cannot proceed.

In addition, the original_indications field is also empty and the mechanism of action is flagged as a data gap. Two upstream data gaps (DG001: package insert warnings/contraindications; DG002: MOA) were identified at the time of Evidence Pack generation, both rated Blocking or High severity. These gaps must be resolved before any mechanistic similarity analysis can be written.

Based on general knowledge, Risdiplam is a well-characterised oral small-molecule SMN2 pre-mRNA splicing modifier approved in multiple markets for Spinal Muscular Atrophy (SMA). However, this information is not present in the submitted Evidence Pack and therefore cannot be used as the basis for an evaluation recommendation. The data pipeline needs to be re-run with the remediation steps below completed first.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The minimum required data to perform a drug repurposing evaluation is absent — predicted_indications is empty and the two upstream blocking data gaps (DG001, DG002) were not resolved before this Evidence Pack was finalised.

To proceed, the following is needed:

[DG001 — Blocking] Download and parse the TFDA package insert PDF to extract key warnings and contraindications; re-run the safety module
[DG002 — High] Query the DrugBank API for Risdiplam (DB15305) to retrieve MOA, drug categories, and toxicity data; populate original_moa
Re-run TxGNN inference after original_indications and original_moa are populated so that predicted_indications returns at least one candidate
Verify original indication list — confirm the approved indication(s) (e.g., SMA) are correctly loaded into the pipeline before re-scoring
Once the above are complete, regenerate the Evidence Pack and re-submit for a full evaluation report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.